Advertisement

Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome

      Abstract

      We tested the hypotheses whether nuclear magnetic resonance (NMR) determined lipoprotein particles, insulin and adiponectin, and C-reactive protein (CRP) and white blood cell (WBC) count as markers of inflammation predicted risk of coronary heart disease (CHD) death among 428 men age 35–57 years with metabolic syndrome (MetSyn) in a matched case control study within the multiple risk factor intervention trial.
      Blood samples collected at entry into the study and stored at −60 °C were obtained from central storage for blood analyte analysis. Two hundred and fourteen men with MetSyn who died of CHD were matched with 214 men with MetSyn who did not die of CHD during 18 years of follow-up. Cases were matched to controls on age, study group, number of factors present in the MetSyn, and presence or absence of a nonfatal CVD event during the trial. Mortality follow-up was determined using the National Death Index.
      Higher levels of high density lipoprotein particles (HDL-P), especially medium-sized HDL-P [hazard ratio (95% confidence interval) 0.45 (0.25–0.83, P < 0.01), quartile 1 as compared to quartile 4], were associated with lower risk of CHD death. Low density lipoprotein (LDL) particles were not associated with increased risk of CHD. Elevated LDL cholesterol (LDL-C), smoking and WBC count were, but levels of adiponectin, insulin and CRP were not significantly related to CHD death. In multivariate models adjusting for smoking and LDL-C, medium HDL-P and WBC count remained independent predictors of CHD death.
      Number of HDL particles, especially medium-sized HDL particles and WBC count were independent predictors of CHD death among men with MetSyn.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Grundy S.M.
        Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
        J Am Coll Cardiol. 2006; 47: 1093-1100
        • Multiple Risk Factor Intervention Trial Research Group
        Risk factor changes and mortality results.
        JAMA. 1982; 248: 1465-1477
        • Neaton J.D.
        • Grimm Jr., R.H.
        • Cutler J.A.
        Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT).
        Contr Clin Trial. 1987; 8: 41S-53S
        • Eberly L.E.
        • Prineas R.
        • Cohen J.D.
        • et al.
        • for the Multiple Risk Factor Intervention Trial Research Group
        Metabolic syndrome: risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial.
        Diabet Care. 2006; 29: 123-130
        • Otvos J.D.
        • Jeyarajah E.J.
        • Bennett D.W.
        Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy.
        Clin Chem. 1991; 37: 377-386
        • Otvos J.D.
        Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.
        Clin Lab. 2002; 48: 171-180
        • Freedman D.S.
        • Otvos J.D.
        • Jeyarajah E.J.
        • Barboriak J.J.
        • Anderson A.J.
        • Walker J.
        Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1046-1053
        • Rosenson R.S.
        • Freedman D.S.
        • Otvos J.D.
        Relations of lipoprotein subclass levels and LDL size to progression of coronary artery disease in the PLAC I trial.
        Am J Cardiol. 2002; 90: 89-94
        • Kuller L.
        • Arnold A.
        • Tracy R.
        • et al.
        NMR spectroscopy of lipoproteins and risk of CHD in the Cardiovascular Health Study.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1175-1180
        • Blake G.J.
        • Otvos J.D.
        • Rifai N.
        • Ridker P.M.
        LDL particle concentration and size as determined by NMR spectroscopy as predictors of cardiovascular disease in women.
        Circulation. 2002; 106: 1930-1937
        • Mackey R.H.
        • Kuller L.H.
        • Sutton-Tyrrell K.
        • Evans R.W.
        • Holubkov R.
        • Matthews K.A.
        Lipoprotein subclasses and coronary artery calcification in postmenopausal women from the Healthy Women Study.
        Am J Cardiol. 2002; 90: 71i-76i
        • Soedamah-Muthu S.S.
        • Chang Y.-F.
        • Otvos J.
        • Evans R.W.
        • Orchard T.J.
        Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
        Diabetologia. 2003; 46: 674-682
        • Freedman D.S.
        • Otvos J.D.
        • Jeyarajah E.J.
        • et al.
        Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study.
        Clin Chem. 2004; 50: 1201-1204
        • Matsuzawa Y.
        Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease.
        Atherosc Suppl. 2005; 6: 7-14
        • Lawlor D.A.
        • Smith G.D.
        • Ebrahim S.
        • Thompson C.
        • Sattar N.
        Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women.
        J Clin Endocrinol Metab. 2005; 90: 5677-5683
        • Pischon T.
        • Girman C.J.
        • Rifai N.
        • Hotamisligil G.S.
        • Rimm E.B.
        Association between dietary factors and plasma adiponectin concentrations in men.
        Am J Clin Nutr. 2005; 81: 780-786
        • Vilarrasa N.
        • Vendrell J.
        • Maravall J.
        • et al.
        Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population.
        Clin Endocrinol. 2005; 63: 329-335
        • Cnop M.
        • Havel P.J.
        • Utzschneider K.M.
        • et al.
        Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.
        Diabetologia. 2003; 46: 459-469
        • Pischon T.
        • Girman C.J.
        • Hotamisligil G.S.
        • Rifai N.
        • Hu F.B.
        • Rimm E.B.
        Plasma adiponectin levels and risk of myocardial infarction in men.
        JAMA. 2004; 291: 1730-1737
        • Kumada M.
        • Kihara S.
        • Sumitsuji S.
        • et al.
        Association of hypoadiponectinemia with coronary artery disease in men.
        Arterioscler Thromb Vasc Biol. 2003; 23: 85-89
        • Benfari R.C.
        The Multiple Risk Factor Intervention Trial (MRFIT). III. The model for intervention.
        Prev Med. 1981; 10: 426-442
        • Widdowson G.M.
        • Kuehneman M.
        • DuChene A.G.
        • Hulley S.B.
        • Cooper G.R.
        Quality control of biochemical data in the Multiple Risk Factor Intervention Trial: central laboratory.
        Contr Clin Trial. 1986; 7: 17S-33S
        • Multiple Risk Factor Intervention Trial Research Group
        Coronary heart disease death, nonfatal acute myocardial infarction, and other clinical outcomes in the Multiple Risk Factor Intervention Trial.
        Am J Cardiol. 1986; 58: 1-13
        • Wentworth D.
        • Neaton J.D.
        • Rasmussen W.
        An evaluation of the Social Security Administration Master Beneficiary Record Index file and the National Death Index in the ascertainment of vital status.
        Am J Public Health. 1982; 73: 1270-1274
        • Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults
        Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Grundy S.M.
        Does the metabolic syndrome exist?.
        Diabet Care. 2006; 29: 1689-1706
        • Kuller L.H.
        • Tracy R.P.
        • Shaten J.
        • Meilahn E.N.
        Relation of C-reactive protein and coronary heart disease in the MRFIT nested case–control study.
        Am J Epidemiol. 1996; 144: 537-547
        • Kuller L.H.
        • Thomas A.
        • Grandits G.
        • for the Multiple Risk Factor Intervention Trial Research Group
        Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.
        Cancer Epidemiol Biomarkers Prev. 2004; 13: 373-377
        • Orchard T.J.
        • Eichner J.
        • Kuller L.H.
        • Becker D.
        • McCallum L.M.
        • Grandits G.A.
        Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial.
        Ann Epidemiol. 1994; 4: 40-45
        • Evans R.W.
        • Shaten J.
        • Hempel J.D.
        • et al.
        • for the MRFIT Research Group
        Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial.
        Arterioscler Thromb Vasc Biol. 1997; 17: 1947-1953
        • Costacou T.
        • Zgibor J.C.
        • Evans R.W.
        • et al.
        The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study.
        Diabetologia. 2005; 48: 41-48
        • Kuller L.H.
        • Matthews K.A.
        • Foran R.F.
        • Edmundowicz D.
        Adiponectin serum levels are determinants of small LDL and coronary calcium among postmenopausal women.
        Circulation. 2003; IV (Abstract): 766
        • Orchard T.J.
        • Eichner J.
        • Kuller L.H.
        • Becker D.J.
        • McCallum L.M.
        • Grandits G.A.
        Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial.
        Ann Epidemiol. 1994; 4: 40-45
        • Kathiresan S.
        • Otvos J.D.
        • Sullivan L.M.
        • et al.
        Increased small low-density lipoprotein particle number. A prominent feature of the metabolic syndrome in the Framingham Heart Study.
        Circulation. 2006; 113: 20-29
        • Otvos J.D.
        • Collins D.
        • Freedman D.S.
        • et al.
        Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
        Circulation. 2006; 113: 1556-1563
      1. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2006. Available at: http://www.elsevier.com/locate/atherosclerosis, in press.

        • Lee J.-Y.
        • Parks J.S.
        ATP-binding cassette transporter AI and its role in HDL formation.
        Curr Opin Lipidol. 2005; 16: 19-25
        • Nambi V.
        • Ballantyne C.M.
        Fat, fit, and leading the charge. Evolution of measuring high-density lipoprotein subpopulations.
        Arterioscler Thromb Vasc Biol. 2005; 25: 2013-2015
        • Asztalos B.F.
        • Collins D.
        • Cupples L.A.
        • et al.
        Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.
        Arterioscler Thromb Vasc Biol. 2005; 25: 2185-2191
        • Morgan J.
        • Carey C.
        • Lincoff A.
        • Capuzzi D.
        High-density lipoprotein subfractions and risk of coronary artery disease.
        Curr Atheroscler Rep. 2004; 6: 359-365
        • Fruchart J.C.
        • Ailhaud G.
        Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance.
        Clin Chem. 1992; 38: 793-797
        • Chirinos J.A.
        • Zambrano J.P.
        • Chakko S.
        • et al.
        Ability of serum to decrease cellular AcylCoA: cholesterol acyl transerferase activity predicts cardiovascular outcomes.
        Circulation. 2005; 112: 2446-2453
        • Barter P.J.
        Cardioprotective effects of high-density lipoproteins. The evidence strengthens.
        Arterioscler Thromb Vasc Biol. 2005; 25: 1305-1306
        • Ferretti G.
        • Bacchetti T.
        • Negre-Salvayre A.
        • Salvayre R.
        • Dousset N.
        • Curatola G.
        Structural modifications of HDL and functional consequences.
        Atherosclerosis. 2006; 184: 1-7
        • Zheng C.
        • Murdoch S.J.
        • Brunzell J.D.
        • Sacks F.M.
        Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans.
        Arterioscler Thromb Vasc Biol. 2006; 26: 891-896
        • Duffy D.
        • Rader D.J.
        Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.
        Circulation. 2006; 113: 1140-1150
        • Aronson D.
        • Goldberg A.
        • Roguin A.
        • et al.
        Effect of obesity on the relationship between plasma C-reactive protein and coronary artery stenosis in patients with stable angina.
        Atherosclerosis. 2006; 185: 137-142